TICKERNERD
Menu
BVSBVSHealthcare · Medical Devices

BVS Stock Forecast: Bioventus, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$14
+0.35% on the day

The 5 Wall Street analysts covering Bioventus, Inc. hold a median 12-month price target of $18 — +25.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 21 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.2B
Ticker Nerd rank
98 / 100
Median analyst target
$18
Analysts covering
5
Total return, dividends reinvested
1W
+0.8%
1M
+21.0%
YTD
+93.3%
1Y
+103.1%
From 52W high
−5.8%
From 52W low
+120.9%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bioventus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Momentum
90
Value
90
Issuance
84
Accruals
82
Growth
78
Revisions
53
Volatility
52
Size
43

Quality (97): The business earns solid, repeatable profits on what it owns.

Volatility (52): The share price moves around a lot.

Size (43): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26BVSHigh $19Median $18Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $15Median $18High $19

The green dot is the last close — the median target sits +25.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Canaccord GenuityMaintainsBuy$15 → $19
17 Aug 2026Cantor FitzgeraldReiteratesOverweight$15
30 June 2026Barrington ResearchMaintainsOutperform—
30 June 2026Barrington ResearchMaintainsOutperform$14
16 June 2026Canaccord GenuityMaintainsBuy—
22 May 2026Barrington ResearchMaintainsOutperform—
6 Mar 2026Barrington ResearchMaintainsOutperform—
6 Mar 2026Craig-HallumMaintainsBuy—
9 Feb 2026Barrington ResearchInitiatesOutperform—
7 July 2025Cantor FitzgeraldInitiatesOverweight—
17 Mar 2025Canaccord GenuityMaintainsBuy—
17 Dec 2024JP MorganUpgradeNeutral—
6 Nov 2024Canaccord GenuityMaintainsBuy—
27 Sept 2024Craig-HallumMaintainsBuy—
13 Aug 2024Canaccord GenuityMaintainsBuy—
7 Aug 2024Craig-HallumMaintainsBuy—
8 May 2024Canaccord GenuityMaintainsBuy—
13 Mar 2024Craig-HallumMaintainsBuy—
7 Dec 2023Canaccord GenuityUpgradeBuy—
3 Apr 2023Craig-HallumMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
0.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

Bioventus, Inc. (BVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
18.4×

Cheaper than 41% of US stocks

Price / sales
1.7×

Cheaper than 52% of US stocks

Price / book
4.3×

Cheaper than 25% of US stocks

EV / EBITDA
15.8×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
3.8%

Higher than 36% of US stocks

Earnings growth (YoY)
348.3%

Higher than 93% of US stocks

Gross margin
69.0%

Higher than 82% of US stocks

Operating margin
12.2%

Higher than 68% of US stocks

Net margin
9.4%

Higher than 69% of US stocks

Returns & dividend
Return on equity
25.7%

Higher than 85% of US stocks

Return on assets
5.5%

Higher than 79% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BVSBioventus, Inc.$1.2B
98
LMRILumexa Imaging Holdings, Inc.$1.2B
2
PRCTPROCEPT BioRobotics Corp.$1.2B
38
IRMDIRadimed Corp.$1.1B
92
IARTIntegra LifeSciences Holdings Corp.$1.3B
90
AORTArtivion, Inc.$1.4B
45
QDELQuidelOrtho Corp.$1.0B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bioventus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BVS news & analysis

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

Zacks Investment Research · 20 Aug 2026positive

Zacks Investment Research published an article suggesting healthcare stocks, including Bioventus (BVS), as portfolio options amid expected Federal Reserve rate hikes and elevated inflation, which could keep markets volatile.

Why it matters — The article highlights BVS as a healthcare stock that investors may consider as a defensive option during periods of market volatility tied to rate hikes.

Is Bioventus (BVS) Stock Undervalued Right Now?

Zacks Investment Research · 7 Aug 2026neutral

Zacks Investment Research published an article questioning whether Bioventus (BVS) stock is undervalued, focusing on its Zacks Rank system that emphasizes earnings estimates and revisions, while also monitoring value, growth, and momentum trends.

Why it matters — BVS watchers would care because the analysis touches on whether the stock may be undervalued based on earnings trends, a key input for investment decisions.

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of Bioventus, Inc.'s Q2 2026 earnings call. The document contains the company's earnings call discussion for that period.

Why it matters — The transcript gives BVS watchers direct access to management's commentary on the quarter's performance and outlook.

Bioventus Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Bioventus reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction, and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.

Why it matters — The results and reaffirmed outlook give BVS watchers a current read on company momentum, growth drivers and financial progress.

Bioventus (BVS) Q2 Earnings Meet Estimates

Zacks Investment Research · 5 Aug 2026neutral

Bioventus (BVS) reported quarterly earnings of $0.22 per share for Q2, meeting the Zacks Consensus Estimate, compared to $0.21 per share in the same quarter last year.

Why it matters — The earnings result matched analyst expectations and showed a slight year-over-year increase, providing a steady performance snapshot for those monitoring Bioventus.

FAQ

Frequently asked questions about BVS stock

What is the BVS stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Bioventus, Inc. have a median 12-month price target of $18, with estimates ranging from $15 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BVS stock a buy right now?

Of the 5 analysts covering Bioventus, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bioventus, Inc. 98 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BVS?

As at 21 Aug 2026, Bioventus, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will BVS stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +25.2% from the last close, and Ticker Nerd's factor model ranks Bioventus, Inc. 98 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BVS stock forecast for 2030?

No analyst covering Bioventus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $19 over the next 12 months.

How has BVS stock performed over the past year?

Bioventus, Inc. returned +103.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bioventus, Inc. do?

Bioventus Inc. Class A Common Stock represents ownership in Bioventus Inc., a medical technology company headquartered in Durham, North Carolina.

What is the latest news on BVS?

The most recent item we track (Zacks Investment Research, 20 Aug 2026): "4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike". Zacks Investment Research published an article suggesting healthcare stocks, including Bioventus (BVS), as portfolio options amid expected Federal Reserve rate hikes and elevated inflation, which could keep markets volatile.

Company

About Bioventus, Inc.

Bioventus Inc. Class A Common Stock represents ownership in Bioventus Inc., a medical technology company headquartered in Durham, North Carolina. Bioventus focuses on developing and commercializing orthobiologic and musculoskeletal treatments that engage and enhance the body’s natural healing processes. Its portfolio is organized into three core business areas: Pain Treatments, Restorative Therapies, and Surgical Solutions. In pain management, the company offers office-based therapies such as hyaluronic acid injections for knee osteoarthritis and peripheral nerve stimulation devices for targeted pain relief. Restorative Therapies include products like the EXOGEN Ultrasound Bone Healing System and other bone-healing stimulation technologies designed to support fracture recovery. Surgical Solutions encompasses a broad range of orthobiologic implants, bone graft substitutes, and ultrasonic surgical systems used in orthopedic, spine, neurosurgery, trauma, and sports medicine procedures. Bioventus primarily serves specialist physicians and hospital-based clinical teams in the United States, complemented by selected international markets, positioning the company as a focused provider of musculoskeletal care products across multiple stages of treatment.

CEO Mr. Robert E. Claypoole · 950 employees · United States · https://www.bioventus.com